Sugi Predict

Sugi Predict / Compounds / SCHEMBL172724

SCHEMBL172724

SCHEMBL172724

CNC(C)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ MMP2 P08253 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ SHBG P04278 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ EPHX1 P07099 3/20 0.35
▸ DAPK3 O43293 1/20 0.34
▸ ROCK2 O75116 1/20 0.34
▸ CHEK2 O96017 1/20 0.34
▸ PIM1 P11309 1/20 0.34
▸ PLK1 P53350 1/20 0.34
▸ ROCK1 Q13464 1/20 0.34
▸ CDC42BPA Q5VT25 1/20 0.34
▸ AURKB Q96GD4 1/20 0.34
▸ PLK3 Q9H4B4 1/20 0.34
▸ MAPKAPK2 P49137 1/20 0.34
▸ TAS1R3 Q7RTX0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22924338 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL178512 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL22924059 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL182054 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL22924061 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL23020214 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL21583727 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL22924352 1.00 CA12 (0.45) CA12CA1CA2MMP2CA9
SCHEMBL17469477 0.97 — —
SCHEMBL3244738 0.97 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107208-A1 COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS THE METHODIST HOSPITAL (US) 2026-05-21 — — WO disclosed
US-11597699-B2 MEK inhibitors and methods of their use EXELIXIS, INC. (US) 2023-03-07 — — US disclosed
CN-109053523-B Azetidines as MEK inhibitors for the treatment of proliferative diseases 埃克塞利希斯股份有限公司 2022-03-25 — — CN disclosed
WO-2022000443-A1 METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS Nanjing Immunophage Biotech Co., Ltd. (CN) 2022-01-06 — — WO disclosed
CN-111643496-A Methods of using MEK inhibitors 埃克塞利希斯股份有限公司 2020-09-11 — — CN disclosed
US-20200283383-A1 MEK Inhibitors and Methods of Their Use EXELIXIS, INC. 2020-09-10 — — US disclosed
WO-2020161663-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. (US) 2020-08-13 — — WO disclosed
US-20200031770-A1 MEK INHIBITORS AND METHODS OF THEIR USE EXELIXIS, INC. 2020-01-30 — — US disclosed
CN-110668988-A Azetidines as MEK inhibitors for the treatment of proliferative diseases 埃克塞利希斯股份有限公司 2020-01-10 — — CN disclosed
US-20190144382-A1 MEK Inhibitors and Methods of Their Use EXELIXIS, INC. 2019-05-16 — — US disclosed
US-5998440-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARPE & DOHME LTD. (GB) 1999-12-07 — — US disclosed
US-5854268-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARP & DOHME, LTD. (GB) 1998-12-29 — — US disclosed
WO-1998050029-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 — — WO disclosed
US-5204353-A 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith CIBA-GEIGY CORPORATION (US) 1993-04-20 — — US disclosed
EP-0288431-B1 3H-1,2,3-triazolo[4,5-d]pyrimidines CIBA-GEIGY AG (CH) 1992-08-19 — — EP disclosed
US-5110818-A Antiepileptic agents CIBA-GEIGY CORPORATION (US) 1992-05-05 — — US disclosed
EP-0363320-A2 Substituted 9H purine CIBA-GEIGY AG (CH) 1990-04-11 — — EP disclosed
EP-0288431-A1 3H-1,2,3-triazolo[4,5-d]pyrimidines CIBA-GEIGY AG (CH) 1988-10-26 — — EP disclosed
EP-0132542-B1 HYDROHALOGENATION OF CONJUGATED DIENES IN THE PRESENCE OF ORGANIC AMINES Union Camp Corporation (US) 1986-10-08 — — EP disclosed
EP-0132542-A1 Hydrohalogenation of conjugated dienes in the presence of organic amines Union Camp Corporation (US) 1985-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283383-A1 MEK Inhibitors and Methods of Their Use BRAF, NRAS, MAP3K20 CA12 4423/4885CA1 4114/4885CA2 3134/4885
US-20190144382-A1 MEK Inhibitors and Methods of Their Use BRAF, NRAS, MAP3K20 CA12 4423/4885CA1 4114/4885CA2 3134/4885
US-11597699-B2 MEK inhibitors and methods of their use BRAF, NRAS, MAP3K20 CA12 4423/4885CA1 4114/4885CA2 3134/4885
US-20200031770-A1 MEK INHIBITORS AND METHODS OF THEIR USE BRAF, NRAS, MAP3K20 CA12 4423/4885CA1 4114/4885CA2 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.